Entities / Company
Theravance Biopharma (United States).
company in San Francisco, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 28
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Viatris and Theravance are collaborating on product sales involving Yupelri, with Viatris recording product sales on August 14, 2025.Some support1 report
-
China approval on 2025-07-15 triggers a payment owed to Theravance Biopharma.Some support1 report
-
Viatris recognized Yupelri net sales, and Theravance sold TRELEGY royalty interest to GSK.Some support2 reports
-
Theravance Biopharma has developed FDA-approved drugs and is currently developing a therapy for MSA patients.Some support3 reports
-
Theravance Biopharma operates within the biopharmaceutical sector and its stock performance was compared against the market index.Some support2 reports
-
Theravance Biopharma completed enrollment in the CYPRESS study for Ampreloxetine, a drug designed to address nOH in MSA.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Theravance Biopharma (United States) this week
News at the entities that move Theravance Biopharma (United States) most-
FDA StructuralAn industrial event related to a manufacturing crisis is triggering regulatory clocks overseen by the FDA.Moves Theravance Biopharma (United States)
-
Royalty Pharma TransactionalFDA granted approvals for RASONQUE and WELTRUZA on November 4, 2026.Moves Theravance Biopharma (United States)
-
MSA OperationalVireo Growth Inc. acquired assets, including PharmaCann and Cannabist Colorado, through MSA.Moves Theravance Biopharma (United States)
-
GSK TransactionalEmma Walmsley, formerly of GSK, has been named CEO of HP Inc. to steer the company through the chip shortage.Moves Theravance Biopharma (United States)
Connections
The 5 strongest of 28, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
FDA formally regulates and approves drugs developed by Theravance Biopharma.
-
Royalty Pharma Transactional
Theravance expects and receives milestone payments from Royalty Pharma based on financial agreements.
-
Cypress Structural
Theravance Biopharma utilizes Cypress's CYPRESS study for clinical trial enrollment and efficacy tracking.
-
MSA Operational
Theravance Biopharma is actively developing therapies targeting MSA patients.
-
GSK Transactional
Theravance sold royalty interests in Trelegy Ellipta to GSK across multiple transactions.
History
Events by the month they beganJune 2026
6 events- Viatris and Theravance are collaborating on product sales involving Yupelri, with Viatris recording product sales on August 14, 2025.
- China approval on 2025-07-15 triggers a payment owed to Theravance Biopharma.
- Viatris recognized Yupelri net sales, and Theravance sold TRELEGY royalty interest to GSK.
- Theravance Biopharma has developed FDA-approved drugs and is currently developing a therapy for MSA patients.
- Theravance Biopharma operates within the biopharmaceutical sector and its stock performance was compared against the market index.
- Theravance Biopharma completed enrollment in the CYPRESS study for Ampreloxetine, a drug designed to address nOH in MSA.